นอร์เวย์ -
นอร์เวย์ -
Statens legemiddelverk
aduvanz 30 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 30 mg
นอร์เวย์ -
นอร์เวย์ -
Statens legemiddelverk
aduvanz 70 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 70 mg
สหภาพยุโรป -
นอร์เวย์ -
EMA (European Medicines Agency)
qinlock
deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.
นอร์เวย์ -
นอร์เวย์ -
Statens legemiddelverk
aduvanz 20 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 20 mg
นอร์เวย์ -
นอร์เวย์ -
Statens legemiddelverk
aduvanz 40 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 40 mg
นอร์เวย์ -
นอร์เวย์ -
Statens legemiddelverk
aduvanz 60 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 60 mg
สหภาพยุโรป -
นอร์เวย์ -
EMA (European Medicines Agency)
clopidogrel ratiopharm
teva b.v. - clopidogrel (as hydrogen sulfate) - myocardial infarction; acute coronary syndrome; peripheral vascular diseases; stroke - antithrombotic agents - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. voksne pasienter som lider av akutt koronar syndrom:ikke-st-segment elevasjon akutt koronar syndrom (ustabil angina eller non-q-bølge myocardial infarction), inkludert pasienter som gjennomgår en stent plassering etter perkutan koronar intervensjon, i kombinasjon med acetylsalisylsyre (asa). st-segment elevasjon akutte myocardial infarction, i kombinasjon med asa i medisinsk behandlede pasienter kvalifisert for trombolytisk behandling. forebygging av atherothrombotic og tromboemboliske hendelser i atrial fibrillationin voksne pasienter med atrieflimmer som har minst en risikofaktor for vaskulære hendelser, er ikke egnet for behandling med vitamin k-antagonister (vka) og som har en lav risiko for blødning, clopidogrel er indisert i kombinasjon med asa for forebygging av atherothrombotic og tromboemboliske hendelser, inkludert hjerneslag.
สหภาพยุโรป -
นอร์เวย์ -
EMA (European Medicines Agency)
raplixa
mallinckrodt pharmaceuticals ireland limited - human fibrinogen, human trombin - hemostase, kirurgisk - antihemoragika - støttende behandling der standard kirurgiske teknikker er utilstrekkelige for forbedring av hemostase. raplixa må brukes i kombinasjon med en godkjent gelatin svamp. raplixa er indisert hos voksne over 18 år.